Are there treatments for atypical parkinsonism? An update on actual options

References

Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., and Londos, E. (2009). Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8, 613–618.10.1016/S1474-4422(09)70146-2Suche in Google Scholar

Antonini, A. and Cilia, R. (2009). Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 32, 475–488.10.2165/00002018-200932060-00004Suche in Google Scholar

Barten, D.M., Fanara, P., Andorfer, C., Hoque, N., Wong, P.Y., Husted, K.H., Cadelina, G.W., Decarr, L.B., Yang, L., Liu, V., et al. (2012). Hyperdynamic microtubules, cognitive deficits, and pathology. J. Neurosci. 32, 7137–7145.10.1523/JNEUROSCI.0188-12.2012Suche in Google Scholar

Berardelli, A., Wenning, G.K., Antonini, A., Berg, D., Bloem, B.R., Bonifati, V., Brooks, D., Burn, D.J., Colosimo, C., Fanciulli, A., et al. (2013). EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur. J. Neurol. 20, 16–34.10.1111/ene.12022Suche in Google Scholar

Brunden, K.R., Ballatore, C., Lee, V.M., Smith, A.B. 3rd, and Trojanowski, J.Q. (2012). Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem. Soc. Trans. 40, 661–666.10.1042/BST20120010Suche in Google Scholar

Daniele, A., Moro, E., and Bentivoglio, A.R. (1999). Zolpidem in progressive supranuclear palsy. N. Engl. J. Med. 341, 543–544. No abstract available. Erratum in: N. Engl. J. Med. 1999. 341, 1632.Suche in Google Scholar

Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., Jones, R., et al. (2010). Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 969–977.10.1016/S1474-4422(10)70194-0Suche in Google Scholar

Fabbrini, G., Barbanti, P., Bonifati, V., Colosimo, C., Gasparini, M., Vanacore, N., and Meco, G. (2001). Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol. Scand. 103, 123–125.10.1034/j.1600-0404.2001.103002123.xSuche in Google Scholar PubMed

Fernandez, H.H., Wu, C.K., and Ott, B.R. (2003). Pharmacotherapy of dementia with Lewy bodies. Expert Opin. Pharmacother. 4, 2027–2037.10.1517/14656566.4.11.2027Suche in Google Scholar PubMed

Freeman, R., Landsberg, L., and Young, J. (1999). The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 53, 2151–2157.10.1212/WNL.53.9.2151Suche in Google Scholar PubMed

Georgiev, D., Danieli, A., Ocepek, L., Novak, D., Zupancic-Kriznar, N., Trost, M., and Pirtosek, Z. (2010). Othello syndrome in patients with Parkinson’s disease. Psychiatr. Danub. 22, 94–98.Suche in Google Scholar

Gilman, S., Wenning, G.K., Low, P.A., Brooks, D.J., Mathias, C.J., Trojanowski, J.Q., Wood, N.W., Colosimo, C., Dürr, A., Fowler, C.J., et al. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676.10.1212/01.wnl.0000324625.00404.15Suche in Google Scholar PubMed PubMed Central

Hoeglinger, G.U., Huppertz, H.J., Wagenpfeil, F.S., Andrés, M.V., Belloch, V., León, T., Del Ser, T., and TAUROS MRI Investigators. (2012). Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial; Alzheimer’s Association International Conference; Vancouver, British Columbia, Canada. Proposal number 34102.Suche in Google Scholar

Lang, A.E. (2005). Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov. Disord. 20, S83–S91.10.1002/mds.20545Suche in Google Scholar

Lee, P.H., Lee, J.E., Kim, H.S., Song, S.K., Lee, H.S., Nam, H.S., Cheong, J.W., Jeong, Y., Park, H.J., Kim, D.J., et al. (2012). A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann. Neurol. 72, 32–40.10.1002/ana.23612Suche in Google Scholar

LeWitt, P.A., Lyons, K.E., Pahwa, R., and SP 650 Study Group. (2007). Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68, 1262–1267.10.1212/01.wnl.0000259516.61938.bbSuche in Google Scholar

LeWitt, P.A., Boroojerdi, B., Surmann, E., Poewe, W., SP716 Study Group, and SP715 Study Group. (2013). Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J. Neural Transm. 120, 1069–1081.10.1007/s00702-012-0925-5Suche in Google Scholar

Ling, H., O’Sullivan, S.S., Holton, J.L., Revesz, T., Massey, L.A., Williams, D.R., Paviour, D.C., Lees, A.J. (2010). Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133, 2045–2057.10.1093/brain/awq123Suche in Google Scholar

Litvan, I., Mangone, C.A, McKee, A., Verny, M., Parsa, A., Jellinger, K., D’Olhaberriague, L., Chaudhuri, K.R., Pearce, R.K. (1996a). Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 60, 615–620.10.1136/jnnp.60.6.615Suche in Google Scholar

Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R.C., Goetz, C.G., Golbe, L.I., Grafman, J., Growdon, J.H., et al. (1996b). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9.10.1212/WNL.47.1.1Suche in Google Scholar

Litvan, I., Phipps, M., Pharr, V.L., Hallett, M., Grafman, J., and Salazar, A. (2001). Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57, 467–473.10.1212/WNL.57.3.467Suche in Google Scholar

Litvan, I., Bhatia, K.P., Burn, D.J., Goetz, C.G., Lang, A.E., McKeith, I., Quinn, N., Sethi, K.D., Shults, C., Wenning, G.K., et al. (2003). Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467–486.10.1002/mds.10459Suche in Google Scholar

Low, P.A., Robertson, D., Gilman, S., Kaufmann, H., Singer, W., Biaggioni, I., Freeman, R., Perlman, S., Hauser, R.A., Cheshire, W., et al. (2014). Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13, 268–275.10.1016/S1474-4422(13)70301-6Suche in Google Scholar

McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., and Spiegel, R. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031–2036.10.1016/S0140-6736(00)03399-7Suche in Google Scholar

McKeith, I., Dickson, D., Lowe, J., Emre, M., O’Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., et al. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863–1872. Erratum in: Eur. J. Neurol. 2013. 20, 406.10.1212/01.wnl.0000187889.17253.b1Suche in Google Scholar

Moretti, D.V., Binetti, G., Zanetti, O., and Frisoni, G.B. (2014a). Rotigotine is safe and efficacious in atypical parkinsonism syndromes induced by both α-synucleinopathy and tauopathy. Neuropsychiatr. Dis. Treat. 10, 1003–1009.10.2147/NDT.S64015Suche in Google Scholar

Moretti, D.V., Binetti, G., Zanetti, O., and Frisoni, G.B. (2014b) Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism. Front. Neurol. 5, 85.10.3389/fneur.2014.00085Suche in Google Scholar

Moretti, D.V., Binetti, G., Zanetti, O., and Frisoni GB. (2014c). Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study. Neuropharmacology 85, 284–289.10.1016/j.neuropharm.2014.05.028Suche in Google Scholar

Mori, E., Ikeda, M., Kosaka, K., and Donepezil-DLB Study Investigators. (2012). Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann. Neurol. 72, 41–52.10.1002/ana.23557Suche in Google Scholar

Novak, P., Williams, A., Ravin, P., Zurkiya, O., Abduljalil, A., Novak, V. (2012). Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 12, 131.10.1186/1471-2377-12-131Suche in Google Scholar

Poewe, W.H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W.H., Martignoni, E., Rupp, M., Boroojerdi, B., and SP 515 Investigators. (2007). Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6, 513–520.10.1016/S1474-4422(07)70108-4Suche in Google Scholar

Poewe, W., Barone, P., Gliadi, N., Gilman, S., Low, P.A., Sampaio, C., Seppi, K., Wenning, G.K., For the Rasagiline-for-MSA Investigators. (2012). A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype. Mov. Disord. 27, 1182.Suche in Google Scholar

Poujois, A., Vidailhet, M., Trocello, J.M., Bourdain, F., Gaymard, B., and Rivaud-Péchoux, S. (2007). Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur. J. Neurol. 14, 1060–1062.10.1111/j.1468-1331.2007.01687.xSuche in Google Scholar PubMed

Ray Chaudhuri, K., Martinez-Martin, P., Antonini, A., Brown, R.G., Friedman, J.H., Onofrj, M., Surmann, E., Ghys, L., and Trenkwalder, C. (2013). Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19, 660–665.10.1016/j.parkreldis.2013.02.018Suche in Google Scholar PubMed

Sanford, M. and Scott, L.J. (2011). Rotigotine transdermal patch: a review of its use in the treatment of Parkinson’s disease. CNS Drugs 25, 699–719.10.2165/11206750-000000000-00000Suche in Google Scholar PubMed

Scheller, D., Stichel-Gunkel, C., Lübbert, H., Porras, G., Ravenscroft, P., Hill, M., and Bezard, E. (2008). Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease. Neurosci. Lett. 432, 30–34.10.1016/j.neulet.2007.12.001Suche in Google Scholar PubMed

Scheller, D., Ullmer, C., Berkels, R., Gwarek, M., and Lübbert, H. (2009). The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch. Pharmacol. 379, 73–86.Suche in Google Scholar

Servello, D., Zekaj, E., Saleh, C., Menghetti, C., and Porta, M. (2014). Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases. Surg. Neurol. Int. 5, S416–S420.10.4103/2152-7806.140208Suche in Google Scholar PubMed PubMed Central

Stamelou, M. and Hoeglinger, G.U. (2013). Atypical parkinsonism: an update. Curr. Opin. Neurol. 26, 401–405.10.1097/WCO.0b013e3283632da6Suche in Google Scholar PubMed PubMed Central

Stamelou, M., Reuss, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K.M., Krisp, A., Menke, T., Schade-Brittinger, C., Oertel, W.H., et al. (2008). Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 23, 942–949.10.1002/mds.22023Suche in Google Scholar PubMed

Stamelou, M., Pilatus, U., Reuss, A., Magerkurth, J., Eggert, K.M., Knake, S., Ruberg, M., Schade-Brittinger, C., Oertel, W.H., and Höglinger, G.U. (2009). In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J. Cereb. Blood Flow Metab. 29, 861–870.10.1038/jcbfm.2009.2Suche in Google Scholar PubMed

Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Höllerhage, M., Oertel, W.H., Müller, U., and Höglinger, G.U. (2010). Rational therapeutic approaches to progressive supranuclear palsy. Brain 133, 1578–1590.10.1093/brain/awq115Suche in Google Scholar PubMed

Stamelou, M., Alonso-Canovas, A., and Bhatia, K.P. (2012). Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov. Disord. 27, 696–702.10.1002/mds.24992Suche in Google Scholar PubMed

Stamelou, M., Quinn, N., and Bhatia, K. (2013). ‘Atypical’ parkinsonism: new genetic disorders presenting with features of PSP, MSA or CBD. Mov. Disord. 28, 1184–1199.10.1002/mds.25509Suche in Google Scholar PubMed

Tsai, R.M. and Boxer, A.L. (2014). Clinical trials: past, current, and future for atypical parkinsonian syndromes. Semin. Neurol. 34, 225–234.10.1055/s-0034-1381739Suche in Google Scholar PubMed PubMed Central

Vilas, D., Pont-Sunyer, C., and Tolosa, E. (2012). Impulse control disorders in Parkinson’s disease. Parkinsonism Relat. Disord. 18, S80–S84.10.1016/S1353-8020(11)70026-8Suche in Google Scholar

Wenning, G.K., Ben-Shlomo, Y., Magalhaes, M., Daniel, S.E., and Quinn, N.P. (1995). Clinicopathological study of 35 cases of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 58, 160–166.10.1136/jnnp.58.2.160Suche in Google Scholar

Wenning, G.K., Tison, F., Ben Shlomo, Y., Daniel, S.E., and Quinn, N.P. (1997). Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 12, 133–147.10.1002/mds.870120203Suche in Google Scholar

Wenning, G.K., Scherfler, C., Granata, R., Bösch, S., Verny, M., Chaudhuri, K.R., Jellinger, K., Poewe, W., and Litvan, I. (1999). Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 67, 620–623.10.1136/jnnp.67.5.620Suche in Google Scholar

Wenning, G.K., Stefanova, N., Jellinger, K.A., Poewe, W., and Schlossmacher, M.G. (2008). Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 64, 239–246.10.1002/ana.21465Suche in Google Scholar

Wenning, G.K., Geser, F., Krismer, F., Seppi, K., Duerr, S., Boesch, S., Köllensperger, M., Goebel, G., Pfeiffer, K.P., Barone, P., et al. (2013). The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 12, 264–274.10.1016/S1474-4422(12)70327-7Suche in Google Scholar

Wesnes, K.A., McKeith, I.G., Ferrara, R., Emre, M., Del Ser, T., Spano, P.F., Cicin-Sain, A., Anand, R., and Spiegel, R. (2002). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement. Geriatr. Cogn. Disord. 13, 183–192.10.1159/000048651Suche in Google Scholar

Williams, D.R. and Lees, A.J. (2009). Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8, 270–279.10.1016/S1474-4422(09)70042-0Suche in Google Scholar

Williams, D.R., de Silva, R., Paviour, D.C., Pittman, A., Watt, H.C., Kilford, L., Holton, J.L., Revesz, T., and Lees, A.J. (2005). Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128, 1247–1258.10.1093/brain/awh488Suche in Google Scholar PubMed

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., Wozniak, D.F., Diamond, M.I., and Holtzman, D.M. (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402–414.10.1016/j.neuron.2013.07.046Suche in Google Scholar PubMed PubMed Central

Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., and Pezzoli, G. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 356, 39–46.10.1056/NEJMoa054830Suche in Google Scholar PubMed

Zhou, C.Q., Li, S.S., Chen, Z.M., Li, F.Q., Lei, P., and Peng, G.G. (2013). Rotigotine transdermal patch in Parkinson’s disease: a systematic review and meta-analysis. PLoS One 8, e69738.10.1371/journal.pone.0069738Suche in Google Scholar PubMed PubMed Central